

UC San Diego

UC San Diego Previously Published Works

Title

Volume of subcortical brain regions in social anxiety disorder: mega-analytic results from 37 samples in the ENIGMA-Anxiety Working Group.

Permalink

<https://escholarship.org/uc/item/5w39z2ws>

Journal

Molecular Psychiatry, 28(3)

Authors

Groenewold, Nynke
Bas-Hoogendam, Janna
Amod, Alyssa
[et al.](#)

Publication Date

2023-03-01

DOI

10.1038/s41380-022-01933-9

Peer reviewed



Published in final edited form as:

Mol Psychiatry. 2023 March ; 28(3): 1079–1089. doi:10.1038/s41380-022-01933-9.

VOLUME OF SUBCORTICAL BRAIN REGIONS IN SOCIAL ANXIETY DISORDER: MEGA-ANALYTIC RESULTS FROM 37 SAMPLES IN THE ENIGMA-ANXIETY WORKING GROUP

A full list of authors and affiliations appears at the end of the article.

Abstract

There is limited convergence in neuroimaging investigations into volumes of subcortical brain regions in social anxiety disorder (SAD). The inconsistent findings may arise from variations in methodological approaches across studies, including sample selection based on age and clinical characteristics. The ENIGMA-Anxiety Working Group initiated a global mega-analysis to determine whether differences in subcortical volumes can be detected in adults and adolescents with SAD relative to healthy controls. Volumetric data from 37 international samples with 1115 SAD patients and 2775 controls were obtained from ENIGMA-standardized protocols for image segmentation and quality assurance. Linear mixed-effects analyses were adjusted for comparisons across seven subcortical regions in each hemisphere using family-wise error (FWE)-correction. Mixed-effects d effect sizes were calculated. In the full sample, SAD patients showed smaller bilateral putamen volume than controls (left: $d=-0.077$, $p_{FWE}=0.037$; right: $d=-0.104$, $p_{FWE}=0.001$), and a significant interaction between SAD and age was found for the left putamen ($t=-0.034$, $p_{FWE}=0.045$). Smaller bilateral putamen volumes (left: $d=-0.141$, $p_{FWE}<0.001$; right: $d=-0.158$, $p_{FWE}<0.001$) and larger bilateral pallidum volumes (left: $d=0.129$, $p_{FWE}=0.006$; right: $d=0.099$, $p_{FWE}=0.046$) were detected in adult SAD patients relative to controls, but no volumetric differences were apparent in adolescent SAD patients relative to controls. Comorbid anxiety disorders and age of SAD onset were additional determinants of SAD-related volumetric differences in subcortical regions. To conclude, subtle volumetric alterations in subcortical regions in SAD were detected. Heterogeneity in age and clinical characteristics may partly explain inconsistencies in previous findings. The association between alterations in subcortical volumes

***CORRESPONDING AUTHOR:** Nynke A. Groenewold, PhD, Address: UCT Neuroscience Centre, E-Floor, Room 34, Groote Schuur Hospital, Anzio Road, Observatory, 7925, Cape Town, South Africa, Tel.: +27 (0)21 406 6843, Fax: +27 (0)21 448 8158, nynke.groenewold@uct.ac.za.

AUTHOR CONTRIBUTIONS

NAG: conceptualization, methodology, data curation, formal analysis, visualization, project administration, writing – original draft; JMBH: conceptualization, methodology, data curation, visualization, project administration, writing – review & editing; ARA: methodology, data curation, formal analysis, project administration, writing – review & editing; MAL, CRKC, NJ: methodology, writing – review & editing; LSV: data curation, methodology, writing – review & editing; MA: conceptualization, writing – review & editing; HO, SPP, IV, LBH, FS, DG, HL, SM, AW, ME, SL, FZ, BM, MJW, AB, MC, HRC, DH, JPe, ANK, BL, CAF, ALG, AHa, AZ, KW, KD, HKI, ES, LS, TMB, GAF, KNTM, AM, SNA, JAC, BF, JCH, AMW: data curation, writing – review & editing; RS, APJ, PMP, GAS, JRB, JH, FRS, KR, NC, JPu, KBB, AJ, TK, AK, IN, UD, QG, JCS, RT, PMW, TS, CL, MJVT, REG, TDS, RB, HJG, HV, JB, PZ, MPP, AS, MBS, HKu, KLP, TF, JUB, CMS, UL, DJV: investigation, writing – review & editing; KH, KSB, AT, BK, AHe, AGGD, EJL: data curation, investigation, writing – review & editing; SIT: project administration, writing – review & editing; DSP: conceptualization, resources, investigation, writing – review & editing; PMT: funding acquisition, conceptualization, methodology, supervision, writing – review & editing; DJS: funding acquisition, conceptualization, resources, investigation, supervision, writing – review & editing; NJAW: funding acquisition, conceptualization, methodology, investigation, supervision, writing – review & editing.

SUPPLEMENTARY INFORMATION

Supplementary information is available at MP's website.

and SAD illness progression deserves further investigation, especially from adolescence into adulthood.

INTRODUCTION

Social anxiety disorder (SAD) is characterized by an intense, disproportionate, and invalidating fear of negative evaluation as may occur in social and performance contexts, leading to severe distress and reduced quality of life (1–3). The condition has a global prevalence of 4–7% (4,5; also see 6), typically starts in early adolescence (7,8) and frequently persists in adulthood (4,6). Many affected individuals develop comorbid psychopathology in addition to SAD, most notably other anxiety and depressive disorders (6,9). Neurobiological models of SAD have emphasized the role of subcortical fear circuitry in social approach-avoidance conflicts and the perception of threat, encompassing the amygdala and hippocampus, and in addition the striatum (10–13). Our understanding of the neurobiology of SAD is incomplete, and conflicting findings regarding morphological differences in subcortical brain regions pose one of the major unknowns¹.

Smaller-scale empirical studies, typically including less than 50 SAD patients, have repeatedly reported volumetric differences relative to controls in the amygdala and hippocampus (14–19). Smaller volumes tend to be reported more frequently in the right hemisphere (16,17; trends in 20,21), however, the direction of effect overall is highly inconsistent (10,22). A more recent voxel-based morphometry mega-analysis investigating amygdala, hippocampus, and striatum regions of interest (ROIs) in 174 adult SAD patients (23) and a retrospective coordinate-based meta-analysis in 470 adolescent and adult SAD patients (24; excluding ROI studies) did not identify volumetric differences in the hippocampus and amygdala. Instead, both studies implicated the putamen, though different subregions and direction of effects. The mega-analysis (23) found a larger gray matter volume in the right dorsal putamen, whereas the meta-analysis (24) reported a smaller left ventral putamen volume in SAD patients. Finally, there is evidence for involvement of the thalamus in SAD (16,24,25). In summary, inconsistent volumetric differences in subcortical regions have been observed in SAD. The findings are difficult to synthesize because of methodological heterogeneity, for example, related to ROI definition and sample selection criteria.

Volumetric differences in subcortical brain regions might be more pronounced in specific subgroups of SAD patients, for example in individuals that are medication-free (smaller thalamus: 24), had an earlier onset of SAD (smaller thalamus, amygdala: 16) and higher symptom severity (smaller amygdala: 14; larger putamen: 23). These isolated findings are in need of replication and point towards interesting open questions. For example, it remains unclear to what extent psychiatric comorbidities impact subcortical volumetric alterations in SAD (26). Furthermore, while most patients develop the condition in adolescence, it is presently unclear whether volumetric differences in subcortical circuitry already manifest in adolescents with SAD (27). The largest study to date (28) identified a smaller right

¹While regions of the frontal cortex also feature in neurobiological models of SAD, the focus of the present investigation is exclusively on subcortical brain regions.

hippocampal volume in 75 young adolescents with an anxiety disorder (mean age: 12 years; age range: 8-18 years). However, in post-hoc analyses this difference was attributed to generalized anxiety disorder (GAD) and not SAD diagnosis. No difference in amygdala volume was detected in these young adolescents (28), and neither in a study of slightly older adolescents with SAD (29; mean age: 16 years; age range: 15-17 years). The abovementioned large, aggregated studies did not include adolescents at all (24) or included an insufficient number of adolescent samples to allow a dedicated sub-analysis (25). While it is plausible that age and clinical characteristics (i.e. psychiatric comorbidity, medication use, age of onset, symptom severity) are of importance for SAD-related volumetric alterations in subcortical regions, this is to be confirmed in well-powered analyses.

The ENIGMA-Anxiety Working Group (overview: 30; preliminary findings: 31) initiated a worldwide effort to perform the largest coordinated multi-site analysis on subcortical volumes in SAD to date, including data on 1115 SAD and 2775 healthy control (HC) participants. In the present investigation, our principal aim was to determine whether alterations in subcortical volumes can be detected in SAD relative to HC participants, using a standardized protocol to harmonize image processing across sites. To optimally address variability within and between samples, volumetric data were pooled in a mega-analysis of individual participant data (in line with: 32,33). The analysis in the aggregated sample was supplemented with a sub-analysis in adolescent participants, thus presenting the first large mega-analysis of subcortical volumes in adolescents with SAD, as well as a sub-analysis in adult participants. Furthermore, SAD-related volumetric differences were examined in relation to psychiatric comorbidity, medication use, age of onset and symptom severity.

MATERIALS AND METHODS

Samples

Volumetric data from 1115 SAD and 2775 HC participants obtained from 37 samples originating from ten countries across five continents, were available for mega-analysis (Table 1). Lifetime or current SAD was established by diagnostic interview (Table 1). Two samples did not assess current SAD (PNC, SHIP). In the other 35 samples, only 2.5% of the total included SAD patients met criteria for lifetime SAD but not current SAD. Exclusion criteria for SAD patients were comorbid schizophrenia (or schizophrenia spectrum disorder), bipolar disorder, and autism spectrum disorder. Exclusion criteria for HCs were lifetime major psychiatric diagnoses and psychotropic medication use at the time of scan, when this information was available. Additional study-specific exclusion criteria applied, as reflected in the sample characteristics (Table 2; Supplemental Table 1). Studies with multiple scan sites (BHRCS, FOR_2107, NESDA) were treated as separate samples per scan site. Individual studies were approved by relevant local ethical review boards and written informed consent was obtained from participants prior to data collection.

Image acquisition and processing

T1-weighted brain magnetic resonance imaging (MRI) scans were acquired at each scan site (1.5T or 3.0T). Details regarding image acquisition and software versions are provided in Supplemental Table 2. MRI scans were processed using the automated

and validated segmentation software package FreeSurfer (34), in accordance with the ENIGMA standardized protocol for brain segmentation and quality assurance (<http://enigma.ini.usc.edu/protocols/imaging-protocols/>). The segmentations of 14 subcortical regions (for each hemisphere: thalamus, amygdala, hippocampus, putamen, pallidum, nucleus accumbens, and caudate; Figure 1) and of the whole brain were visually inspected for accuracy. The distribution and variance of volumes in the total sample and in SAD and HC subgroups were visually inspected to identify potential outliers. Segmentations that did not pass quality control were excluded from analysis (approach detailed in Supplemental Note 1).

Linear mixed-effects models

A series of linear models were fitted with volume per subcortical region as outcome variable and SAD diagnosis (dichotomous factor) or symptom severity (continuous variable) as main regressor. The following covariates were used: sex, age, age², sex-by-age, sex-by-age² and total intracranial volume (ICV). Age was centred throughout. Mixed-effects *d* effect sizes were calculated from the *t*-values for diagnostic factor, and mixed-effects *r* estimates were calculated for relevant interaction and continuous variables of interest (Supplemental Note 1). These are similarly scaled as Cohen's *d* estimates and *r* estimates, but include a correction for non-independence in the aggregated dataset (35). Throughout the analyses, samples were only included for between-group contrasts when at least one observation per group was available for each of the subcortical regions. The threshold for significance was set at family-wise error (FWE)-corrected $p < 0.05$, adjusting for 14 subcortical regions ($p_{\text{unc}} < 0.00357$) in all analyses.

First, the full SAD sample was compared to all HCs. In sensitivity analyses, SAD patients were excluded for comorbid lifetime obsessive-compulsive disorder (OCD; excluded: comorbid OCD: $n=29$; OCD not assessed: $n=178$), lifetime post-traumatic stress disorder (PTSD; excluded: comorbid PTSD: $n=66$; PTSD not assessed: $n=155$), or were excluded when current SAD criteria were not met (lifetime but not current SAD: $n=21$; current SAD not assessed: $n=184$). Next, SAD *diagnosis-by-sex*, *diagnosis-by-age* and *diagnosis-by-age*² interactions were tested in the full sample. SAD versus HC comparisons were also made according to *age group* cf. (36): child/adolescent SAD versus HC (range: 8-21 years; hereafter abbreviated to adolescent SAD) and adult SAD versus HC (range: 22-69 years).

Next, clinical characteristics of SAD were investigated in relation to subcortical volumes. The following characteristics were used to define SAD subgroups: *comorbid anxiety disorders* (lifetime generalized anxiety disorder, panic disorder, agoraphobia, specific phobia, or any other anxiety diagnoses that were assessed), *psychotropic medication use* at the time of scan, and *early onset of disease* (<13 years according to median onset; see Supplementary Note 1). SAD patients with and without these characteristics were separately contrasted with HCs. As clinical characteristics differed considerably between adult and adolescent SAD patients, sensitivity analyses were conducted in adult and adolescent age groups when appropriate (5 samples with total 100 adult or adolescent SAD patients per clinical subgroup; Table 3). For completeness, SAD patients with and without the relevant clinical characteristics were also contrasted directly in supplemental subgroup analyses.

Additional supplemental subgroup analyses (SAD relative to HCs) were conducted for SAD patients with and without lifetime major depressive disorder (MDD) comorbidity, and medication use restricted to selective serotonin reuptake inhibitors (SSRI) and serotonin-noradrenaline reuptake inhibitors (SNRI), because of their overlapping mechanisms of action. Finally, associations between subcortical volumes and *symptom severity* were examined in SAD patients. Severity of social anxiety was measured with the Liebowitz Social Anxiety Scale (LSAS total score; 37) in 21 samples (total $n=523$), trait anxiety with the State-Trait Anxiety Inventory (STAI trait score; 38) in 19 samples (total $n=539$), and depressive symptoms with the Beck Depression Inventory second edition (BDI-II total score; 38) in 19 samples (total $n=409$).

Selection mega-analytic approach

All linear mixed-effects models were fitted with a random-intercept to account for data clustering within samples. Both models with a random slope for diagnosis per sample (complex model) and without random slope (reference model) were fitted, and fit was compared using the Likelihood Ratio Test (LRT; cf. 33, $p<0.05$ indicates improved model fit in complex relative to reference model). The mega-analytic model with the best model fit for the majority of subcortical regions was selected, based on the full sample. All mega-analysis models were fitted with restricted maximum likelihood (ReML; 40) in R version 3.6.3 (nlme package) and mixed-effects d and r effect sizes were computed (Supplemental Note 1).

Data and code availability

The ENIGMA-Anxiety Working Group is open to sharing the data and code from this investigation to researchers for secondary data analysis. Code can be requested from the corresponding author. To request access to volumetric, clinical, and demographic data, an analysis plan can be submitted to the ENIGMA-Anxiety Working Group (<http://enigma.ini.usc.edu/ongoing/enigma-anxiety/>). Data access is contingent on approval by PIs from contributing samples.

RESULTS

Model fit

Model fit comparisons were conducted on data from 37 samples with a total of 1115 SAD patients and 2775 HCs (full aggregated sample). The inclusion rate of volumetric observations after quality control was 97.7% across all subcortical regions. For 9/14 subcortical regions, the complex model with random intercept (scan site) and random slope (SAD diagnosis per scan site) did not show a significant improvement in model fit compared to the random intercept (scan site) reference model (Supplemental Table 3). Hence, all subsequent analyses were conducted with the random intercept (scan site) model.

Subcortical brain volumes in social anxiety disorder relative to controls

An overview of findings from the main and subgroup analyses is provided in Table 3. SAD patients (full sample including current and lifetime SAD diagnoses) showed a smaller volume of the bilateral putamen (left putamen: mixed-effects $d=-0.077$, $p_{FWE}=0.037$; right putamen: mixed-effects $d=-0.104$, $p_{FWE}=0.001$) compared to HCs (Figure 2). The effect

sizes were robust in three sensitivity analyses, excluding SAD patients with comorbid OCD, comorbid PTSD, or no current SAD diagnosis (range in mixed-effects d for left putamen $[-0.094, -0.074]$; right putamen $[-0.120, -0.108]$), although the left putamen was no longer significant when restricting the analysis to current SAD versus HCs (mixed-effects $d=-0.074$, $p_{FWE}=0.156$; Supplemental Table 4a–b).

Social anxiety disorder interactions with age and sex

In the full sample, a significant negative interaction between SAD diagnosis and age was found for the left putamen (mixed-effects $t=-0.034$, $p_{FWE}=0.045$). Analyses by age group provided more insight into this negative interaction. The mega-analysis in adults revealed smaller volumes of the bilateral putamen (left putamen: mixed-effects $d=-0.141$, $p_{FWE}<0.001$; right putamen: mixed-effects $d=-0.158$, $p_{FWE}<0.001$) and larger volumes of the bilateral pallidum (left pallidum: mixed-effects $d=0.129$, $p_{FWE}=0.006$; right pallidum: mixed-effects $d=0.099$, $p_{FWE}=0.046$) in SAD patients compared to HCs. However, there were no significant differences between adolescents with SAD and adolescent HCs (Figure 2; Supplemental Table 5a–b). Furthermore, there were no significant interactions between SAD and sex, nor between SAD and age² in the full sample (Supplemental Note 2).

Social anxiety disorder subgroups: comorbid anxiety disorders

SAD patients with a comorbid anxiety disorder showed a significantly smaller left amygdala volume (mixed-effects $d=-0.145$, $p_{FWE}=0.017$) compared to HCs (Table 3). This volumetric difference did not reach significance when selectively including adult SAD patients with comorbid anxiety, despite a similar effect size (mixed-effects $d=-0.174$, $p_{FWE}=0.077$); and neither in adolescent SAD patients with comorbid anxiety (mixed-effects $d=-0.110$, $p_{FWE}=1.000$). Furthermore, smaller bilateral putamen volumes (left putamen: mixed-effects $d=-0.091$, $p_{FWE}=0.046$; right putamen: mixed-effects $d=-0.097$, $p_{FWE}=0.029$) were observed in SAD patients without a comorbid anxiety disorder compared to HCs (SAD subgroups compared to HCs presented in Supplemental Tables 6–8; contrasts between SAD subgroups in Supplemental Note 4). The smaller bilateral putamen finding replicated in adult SAD patients without comorbid anxiety, but not in adolescent SAD patients without comorbid anxiety. Of note, the volumetric differences observed for SAD subgroups with and without comorbid MDD were highly similar to the findings for comorbid anxiety disorders (Supplemental Note 3).

Social anxiety disorder subgroups: psychotropic medication use

No FWE-corrected significant differences in subcortical volumes were observed for SAD patients that used psychotropic medication at the time of scan compared to HCs. This also applied to the subset of SAD patients that specifically used SSRIs or SNRIs. SAD patients without psychotropic medication use at the time of scan showed a smaller right putamen volume (mixed-effects $d=-0.100$, $p_{FWE}=0.007$) compared to HCs, and this difference was also significant when restricting the analysis to adult SAD patients without psychotropic medication (Table 3).

Social anxiety disorder subgroups: early and later onset

SAD patients with early onset demonstrated a smaller right hippocampus volume (mixed-effects $d=-0.194$, $p_{FWE}=0.009$) compared to HCs. This finding was stronger in adult SAD with early onset (mixed-effects $d=-0.326$, $p_{FWE}<0.001$). In SAD patients with later onset compared to HCs, smaller bilateral putamen (left putamen: mixed-effects $d=-0.336$, $p_{FWE}<0.001$; right putamen: mixed-effects $d=-0.309$, $p_{FWE}<0.001$) and left nucleus accumbens (mixed-effects $d=-0.171$, $p_{FWE}=0.024$) volumes were found. In addition, larger bilateral pallidum volumes (left pallidum: mixed-effects $d=0.240$, $p_{FWE}=0.002$; right putamen: mixed-effects $d=0.195$, $p_{FWE}=0.006$) were observed. Most findings for later-onset SAD replicated in the adult subgroup (left putamen: mixed-effects $d=-0.362$, $p_{FWE}<0.001$; right putamen: mixed-effects $d=-0.322$, $p_{FWE}<0.001$; left pallidum: mixed-effects $d=0.260$, $p_{FWE}=0.001$; right pallidum: mixed-effects $d=0.199$, $p_{FWE}=0.006$). However, significance for the left nucleus accumbens was lost (Table 3).

Severity of social anxiety, trait anxiety and depressive symptoms

No significant associations were detected between subcortical volumes and the severity of social anxiety, trait anxiety, or depressive symptoms in SAD patients after FWE-correction for multiple comparisons (associations at $p_{unc}<0.05$ presented in Supplemental Note 5).

DISCUSSION

In this study, the ENIGMA-Anxiety Working Group investigated differences in volume of subcortical brain regions between SAD patients and HCs, including 37 samples from research sites worldwide. We found evidence for subtle subcortical volumetric differences in patients with SAD relative to controls, involving regions previously implicated in social approach-avoidance conflicts and the perception of threat. The most pertinent finding across the conducted mega-analyses concerned smaller volumes of the bilateral putamen in SAD patients compared to HC participants. Volumetric alterations differed across age groups: smaller volumes of the bilateral putamen and larger volumes of the bilateral pallidum were observed in adult SAD patients, but no differences were observed in adolescent SAD patients. Comorbid anxiety disorders and early age of onset were additional determinants of SAD-related volumetric alterations, revealing smaller volumes of the left amygdala and right hippocampus, respectively. Thus, heterogeneity in age and clinical characteristics may partly explain the inconsistent findings previously reported in the literature.

The smaller bilateral putamen in SAD patients aligns with the previous meta-analytic result of a smaller left putamen (24); also see (41,42). In our mega-analyses, smaller putamen volumes were accompanied by larger pallidum volumes in adult SAD as well as in SAD subgroups without comorbidity or medication use, and with later onset of the condition. The sample included in a previous voxel-based morphometry mega-analysis (23; this sample partly overlaps with presently investigated sample) had relatively similar characteristics and showed a larger volume in the right dorsal putamen, extending into the pallidum. Enlargement of the left pallidum was also found to be positively related to social anxiety symptoms in families genetically enriched for SAD (43). The prior mega-analytic finding (23) may therefore reflect a signal originating in the pallidum or a regional volumetric

extension of the putamen adjacent to the pallidum. Future vertex-wise analysis of the shape of subcortical regions (cf. 44,45) might be able to locate group differences more precisely and shed light on this matter. The role of the basal ganglia complex in reward processing deficiencies has previously been emphasized in relation to inhibited temperament and anxiety in adolescence (11). In these groups, aberrant putamen activation has been proposed to reflect an intense desire to avoid failure in social contexts. Less is known about the pallidum in relation to motivational deficiencies in SAD (11). Thus, the functional role of the putamen and pallidum in positive and negative emotional processing in adult and adolescent SAD deserves further investigation (11,46,47).

The use of standardized ENIGMA protocols allows us to compare the volumetric differences observed for SAD to other psychiatric conditions previously examined with a similar approach. The combination of smaller putamen and larger pallidum volumes has not been observed for other psychiatric conditions examined in ENIGMA Working Groups (48). The findings for SAD contrast with the subthreshold enlargement of left and right putamen volume in GAD patients previously reported by our Working Group (45). Larger pallidum volumes, but no difference in putamen volumes, have been reported in adult OCD patients by the ENIGMA-OCD Working Group (49). Furthermore, smaller putamen and pallidum volumes have been reported by the ENIGMA-Autism Spectrum Disorder Working Group (50). In the present study, the effect sizes observed for SAD were small (mixed-effects d ranging from approximately -0.10 in the main analysis to -0.30 in late-onset SAD versus HCs; 51). Mixed-effects d estimates are comparable to Cohen's d estimates, although mixed-effects estimates can be slightly attenuated through better adjustment for between-sample variance (35). Effect sizes for SAD are thus comparable in magnitude to those observed in ENIGMA studies of the anxiety-related conditions OCD, PTSD, and MDD (Cohen's d approximately -0.15 for bilateral hippocampus in main analyses; 48,52,53), but are substantially smaller than previously observed for schizophrenia (Cohen's d -0.46 for bilateral hippocampus; 54).

The observed smaller left amygdala in SAD patients with comorbid anxiety disorders and comorbid MDD in the present study concurs with previous findings in adolescents (17), young adults with SAD (16), and male adult SAD patients (14), although prior findings more consistently involved the right amygdala. Amygdala involvement in fear processing is possibly functionally lateralized; the right amygdala has been implicated in rapid fear responsivity whereas the left amygdala is thought to be involved in elaborate and stimulus-specific appraisals of anxiety (55–57). The latter of these functional specializations might bear relevance to the present findings. Interestingly, concordance in genetic variation has been identified between risk for anxiety disorders and smaller amygdala volumes (58), providing a possible explanation for the more pronounced amygdala alterations in SAD patients with comorbid anxiety. Of note, the ENIGMA-MDD Working Group reported no significant differences in bilateral amygdala volumes related to MDD diagnosis or comorbid anxiety disorders. Yet, smaller volumes of the bilateral hippocampus were found in early onset MDD relative to HCs (53; more pronounced than in the full MDD sample), similar to the presently observed smaller right hippocampal volume in early onset SAD. The effect size for early onset SAD was substantially higher in the adult subsample compared to the full age range sample (i.e., when also including children and adolescents). This

could possibly reflect an association with longer illness duration, in line with the smaller hippocampal volumes that have been observed in recurrent MDD (53).

Here, we present the largest study to date investigating subcortical volumes in SAD patients. We extend prior literature by adopting a mega-analytic approach with standardized protocols for processing and quality control across the contributing samples that facilitated comparisons with psychiatric conditions previously studied within the ENIGMA Consortium, and by utilizing our large dataset to extensively explore clinical characteristics that are associated with volumetric differences in SAD patients. While harmonization was accomplished to a certain degree, several sources of methodological heterogeneity remained (e.g., field strength, scan sequence, FreeSurfer version). Furthermore, analyses needed to be restricted to variables that were consistently collected across the samples. This resulted in a relatively modest sample size and limited variability for analyses of symptom severity, although the sample size is substantially larger than in previous studies on SAD (for example $n=148$; 23). Finally, limitations of the source datasets (involving cross-sectional and in part retrospective designs) also applied to the aggregated dataset. Relatively few of the SAD participants were taking psychotropic medication at the time of scan, and few no longer met diagnostic criteria for current SAD. This resulted in limited power to investigate these factors and could be suggestive of selection bias. Longitudinal research will need to delineate the trajectory of volumetric alterations in subcortical regions in SAD patients (cf. 59), to confirm whether volumetric differences in subcortical regions are stable over time in specific clinical SAD subgroups or newly emerge following critical stages of development and possibly aggravate with longer illness duration.

To conclude, the largest coordinated multi-site analysis on subcortical volumes in SAD to date revealed subtle volumetric alterations in subcortical brain regions implicated in emotional processing in SAD, with the most noteworthy and consistent finding concerning smaller volumes in the bilateral putamen. The magnitude of these volumetric differences appears to be comparable to those observed in other anxiety-related psychiatric conditions, although the implicated subcortical regions are partly distinct. Age and clinical characteristics are probable determinants of volumetric alterations in subcortical regions in SAD patients, suggesting that these perhaps aggravate with prolonged illness duration. The ENIGMA-Anxiety Working Group will next conduct a large multi-site analysis on cortical thickness and cortical surface area in SAD, to examine whether age and clinical characteristics are determinants of alterations in these brain features as well. Further research is needed to delineate how SAD-related alterations in brain structure are associated with SAD illness progression, investigating persistence and remission of symptoms in adolescence and adulthood.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Nynke A. Groenewold, PhD^{1,2,*}, Janna Marie Bas-Hoogendam, PhD^{3,4,5}, Alyssa R. Amod, MSc¹, Max A. Laansma, MSc⁶, Laura S. Van Velzen, PhD⁷, Moji Aghajani, PhD⁸, Kevin Hilbert, PhD⁹, Hyuntaek Oh, PhD¹⁰, Ramiro Salas, PhD^{10,11}, Andrea P. Jackowski, PhD¹², Pedro M. Pan, MD, PhD¹², Giovanni A. Salum, MD, PhD¹³, James R. Blair, PhD¹⁴, Karina S. Blair, PhD¹⁵, Joy Hirsch, PhD¹⁶, Spiro P. Pantazatos, PhD^{17,18}, Franklin R. Schneier, MD^{17,18}, Ardesheer Talati, PhD^{17,18}, Karin Roelofs, PhD¹⁹, Inge Volman, PhD²⁰, Laura Blanco-Hinojo, PhD^{21,22}, Narcís Cardoner, MD, PhD^{23,24,25}, Jesus Pujol, MD, PhD^{21,22}, Katja Beesdo-Baum, PhD²⁶, Christopher R. K. Ching, PhD²⁷, Sophia I. Thomopoulos, BA²⁷, Andreas Jansen, PhD²⁸, Tilo Kircher, MD, PhD²⁹, Axel Krug, PhD^{29,30}, Igor Nenadi, MD²⁹, Frederike Stein, PhD²⁹, Udo Dannlowski, MD, PhD³¹, Dominik Grotegerd, PhD³¹, Hannah Lemke, MSc³¹, Susanne Meinert, MSc^{31,32}, Alexandra Winter, MSc³¹, Michael Erb, PhD³³, Benjamin Kreifelts, MD³⁴, Qiyong Gong, MD, PhD^{35,36}, Su Lui, MD, PhD^{35,36}, Fei Zhu, MSc^{35,36}, Benson Mwangi, PhD³⁷, Jair C. Soares, MD, PhD³⁷, Mon-Ju Wu, PhD³⁷, Ali Bayram, PhD³⁸, Mesut Canli, MD³⁹, Ra it Tükel, MD⁴⁰, P. Michiel Westenberg, PhD^{4,5}, Alexandre Heeren, PhD⁴¹, Henk R. Cremers, PhD⁴², David Hofmann, PhD⁴³, Thomas Straube, PhD⁴³, Alexander G. G. Doruyter, PhD⁴⁴, Christine Lochner, PhD⁴⁵, Jutta Peterburs, PhD⁴⁶, Marie-José Van Tol, PhD⁴⁷, Raquel E. Gur, MD, PhD⁴⁸, Antonia N. Kaczurkin, PhD⁴⁹, Bart Larsen, PhD⁴⁸, Theodore D. Satterthwaite, MD⁴⁸, Courtney A. Filippi, PhD⁵⁰, Andrea L. Gold, PhD⁵¹, Anita Harrewijn, PhD^{50,52}, André Zugman, MD, PhD⁵⁰, Robin Bülow, MD⁵³, Hans J. Grabe, MD^{54,55}, Henry Völzke, MD⁵⁶, Katharina Wittfeld, PhD^{54,55}, Joscha Böhnlein, PhD³¹, Katharina Dohm, PhD³¹, Harald Kugel, PhD⁵⁷, Elisabeth Schrammen, MSc³¹, Peter Zwanzger, MD^{58,59}, Elisabeth J. Leehr, PhD³¹, Lisa Sindermann, MSc⁶⁰, Tali M. Ball, PhD⁶¹, Gregory A. Fonzo, PhD⁶², Martin P. Paulus, MD⁶³, Alan Simmons, PhD⁶⁴, Murray B. Stein, MD, MPH⁶⁵, Heide Klumpp, PhD⁶⁶, K. Luan Phan, MD⁶⁷, Tomas Furmark, PhD⁶⁸, Kristoffer N. T. Månsson, PhD⁶⁹, Amirhossein Manzouri, MSc⁶⁹, Suzanne N. Avery, PhD⁷⁰, Jennifer Urbano Blackford, PhD⁷¹, Jacqueline A. Clauss, MD, PhD⁷², Brandee Feola, PhD⁷⁰, Jennifer C. Harper, MS⁷³, Chad M. Sylvester, MD, PhD⁷³, Ulrike Lueken, PhD⁹, Dick J. Veltman, MD, PhD⁷⁴, Anderson M. Winkler, MD, DPhil⁵⁰, Neda Jahanshad, PhD²⁷, Daniel S. Pine, MD, PhD⁵⁰, Paul M. Thompson, PhD²⁷, Dan J. Stein, MD, PhD^{1,75}, Nic J. A. Van der Wee, MD, PhD^{3,5}

Affiliations

¹Neuroscience Institute, Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa

²South African Medical Research Council (SA-MRC) Unit on Child and Adolescent Health, Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, University of Cape Town, Cape Town, South Africa

³Department of Psychiatry, Leiden University Medical Center, Leiden, Netherlands

4. Department of Developmental and Educational Psychology, Institute of Psychology, Leiden University, Leiden, Netherlands
5. Leiden Institute for Brain and Cognition, Leiden, Netherlands
6. Department of Anatomy & Neurosciences, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
7. Orygen & Centre for Youth Mental Health, The University of Melbourne, Melbourne, Australia
8. Leiden University, Institute of Education & Child Studies, Section Forensic Family & Youth Care, Leiden, Netherlands
9. Department of Psychology, Humboldt-Universität zu Berlin, Berlin, Germany
10. Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA
11. Michael E DeBakey VA Medical Center, Center for Translational Research on Inflammatory Diseases, Houston, TX, USA
12. LiNC, Department of Psychiatry, Federal University of São Paulo, São Paulo, SP, Brazil
13. Section on Negative Affect and Social Processes, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
14. Child and Adolescent Mental Health Centre, Mental Health Services, Capital Region of Denmark, Copenhagen, Denmark
15. Center for Neurobehavioral Research, Boys Town National Research Hospital, Boys Town, NE, USA
16. Departments of Psychiatry & Neurobiology, Yale School of Medicine, New Haven, CT, USA
17. Department of Psychiatry, Columbia University Medical Center, New York, NY, USA
18. New York State Psychiatric Institute, New York, NY, USA
19. Donders Institute for Brain, Cognition and Behavior, Radboud University Behavioral Science Institute, Radboud University, Nijmegen, Netherlands
20. Wellcome Centre for Integrative Neuroimaging (WIN), Centre for Functional MRI of the Brain (FMRIB), Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom
21. MRI Research Unit, Department of Radiology, Hospital del Mar, Barcelona, Spain
22. Centro Investigación Biomédica en Red de Salud Mental, CIBERSAM G21, Barcelona, Spain
23. Department of Mental Health, University Hospital Parc Taulí-I3PT, Barcelona, Spain

24. Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
25. Centro de Investigación Biomédica en Red de Salud Mental, Carlos III Health Institute, Madrid, Spain
26. Behavioral Epidemiology, Institute of Clinical Psychology and Psychotherapy, Technische Universität Dresden, Dresden, Germany
27. Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA, USA
28. Core-Facility Brainimaging, Faculty of Medicine, University of Marburg, Marburg, Germany
29. Department of Psychiatry, University of Marburg, Marburg, Germany
30. Department of Psychiatry, University Hospital of Bonn, Bonn, Germany
31. Institute for Translational Psychiatry, University of Münster, Münster, Germany
32. Institute for Translational Neuroscience, University of Münster, Münster, Germany
33. Department of Biomedical Magnetic Resonance, University of Tübingen, Tübingen, Germany
34. Department of Psychiatry and Psychotherapy, Tübingen Center for Mental Health (TüCMH), University of Tübingen, Tübingen, Germany
35. Huaxi MR Research Center (HMRRRC), Functional and Molecular Imaging Key Laboratory of Sichuan Province, Department of Radiology, West China Hospital of Sichuan University, Chengdu, China
36. Research Unit of Psychoradiology, Chinese Academy of Medical Sciences, Chengdu, China
37. Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston, Houston, TX, USA
38. Department of Neuroscience, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey
39. Department of Physiology, Istanbul University, Istanbul, Turkey
40. Department of Psychiatry, Istanbul University, Istanbul, Turkey
41. Psychological Science Research Institute, Université Catholique de Louvain, Louvain-la-Neuve, Belgium
42. Department of Clinical Psychology, University of Amsterdam, Amsterdam, Netherlands
43. Institute of Medical Psychology and Systems Neuroscience, University of Münster, Münster, Germany

44. Division of Nuclear Medicine, Stellenbosch University, Stellenbosch, South Africa
45. SA-MRC Unit on Risk and Resilience in Mental Disorders, Stellenbosch University, Stellenbosch, South Africa
46. Institute of Systems Medicine and Faculty of Human Medicine, MSH Medical School Hamburg, Hamburg, Germany
47. Cognitive Neuroscience Center, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
48. Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA
49. Department of Psychology, Vanderbilt University, Nashville, TN, USA
50. Emotion and Development Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
51. Department of Psychiatry and Human Behavior, Brown University Warren Alpert Medical School, Providence, RI, USA
52. Department of Psychology, Education and Child Studies, Erasmus University Rotterdam, Rotterdam, Netherlands
53. Institute for Diagnostic Radiology and Neuroradiology, University Medicine Greifswald, Greifswald, Germany
54. Department of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany
55. German Center for Neurodegenerative Diseases (DZNE), Site Rostock/ Greifswald, Greifswald, Germany
56. Institute for Community Medicine, University Medicine Greifswald, Greifswald, Germany
57. University Clinic for Radiology, University of Münster, Münster, Germany
58. KBO-Inn-Salzach-Klinikum, Munich, Germany
59. Department of Psychiatry and Psychotherapy, Ludwig Maximilians University of Munich, Munich, Germany
60. Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany
61. Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA
62. Department of Psychiatry and Behavioral Sciences, The University of Texas at Austin Dell Medical School, Austin, TX, USA
63. Laureate Institute for Brain Research, Tulsa, OK, USA
64. Department of Psychiatry, University of California, San Diego, La Jolla, CA, USA

- ⁶⁵.Departments of Psychiatry & School of Public Health, University of California, San Diego, La Jolla, CA, USA
- ⁶⁶.Departments of Psychology & Psychiatry, University of Illinois at Chicago, Chicago, IL, USA
- ⁶⁷.Department of Psychiatry & Behavioral Health, the Ohio State University, Columbus, OH, USA
- ⁶⁸.Department of Psychology, Uppsala University, Uppsala, Sweden
- ⁶⁹.Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
- ⁷⁰.Department of Psychiatry and Behavioral Sciences, Vanderbilt University Medical Center, Nashville, TN, USA
- ⁷¹.Munroe-Meyer Institute, University of Nebraska Medical Center, Omaha, NE, USA
- ⁷².Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- ⁷³.Department of Psychiatry, Washington University, St. Louis, MO, USA
- ⁷⁴.Department of Psychiatry, Amsterdam UMC location VUMC, Amsterdam, Netherlands
- ⁷⁵.SA-MRC Unit on Risk & Resilience in Mental Disorders, University of Cape Town, Cape Town, South Africa

ACKNOWLEDGEMENTS

ENIGMA acknowledges the NIH Big Data to Knowledge (BD2K) award for foundational support and consortium development (U54 EB020403 to PMT). For a complete list of ENIGMA-related grant support please see here: <http://enigma.ini.usc.edu/about-2/funding/>. NAG was supported by a Developing Emerging Academic Leaders Fellowship. This work was made possible in part by a grant from Carnegie Corporation of New York. JMBH was supported by a Rubicon grant from the Dutch Research Council NWO (019.201SG.022). ARA, CL and DJS were supported by the South African Medical Research Council (SA-MRC). DJS and NJAW were supported by the EU7th Frame Work Marie Curie Actions International Staff Exchange Scheme grant “European and South African Research Network in Anxiety Disorders” (EUSARNAD). NJAW was also supported by the Anxiety Disorders Research Network European College of Neuropsychopharmacology.

The Leiden Family Lab study on Social Anxiety Disorder (LFLSAD) was funded by Leiden University Research Profile ‘Health, Prevention and the Human Life Cycle’. The infrastructure for the NESDA study (www.nesda.nl) is funded through the Geestkracht program of the Netherlands Organisation for Health Research and Development (ZonMw, grant number 10-000-1002) and financial contributions by participating universities and mental health care organizations (VU University Medical Center, GGZ inGeest, Leiden University Medical Center, Leiden University, GGZ Rivierduinen, University Medical Center Groningen, University of Groningen, Lentis, GGZ Friesland, GGZ Drenthe, Rob Giel Onderzoekscentrum). SHIP is part of the Community Medicine Research Network of the University Medicine Greifswald, which is supported by the German Ministry of Education and Research (BMBF) and a joint grant from Siemens Healthineers, Erlangen, Germany and the Federal State of Mecklenburg-West Pomerania.

This work was supported by multiple grants from the German Research Foundation (DFG): FOR5187 grant (HI 2189/4-1) - KH; grant BE 3809/8-1 - KBB, grants (JA 1890/7-1, JA 1890/7-2) - AJ; grants FOR2107 (KI588/14-1, KI588/14-2) - TK; grants (KR 3822/7-1, KR 3822/7-2) -AK; grants (NE2254/1-2, NE2254/3-1, NE2254/4-1) - IN; grants (DA1151/5-1, DA1151/5-2) - UD; FOR5187 grant (KR 4398/5-1) - BK; (SFB/TRR 58: C06, C07) - TS; grants (LU 1509/9-1, LU 1509/10-1, LU 1509/11-1) - UL. UD was additionally supported by the Interdisciplinary Center for Clinical Research (IZKF) of the medical faculty of Münster (grant Dan3/012/17 to UD).

This work was further supported by the NIH through multiple grants. MPP, MBS, TMB and AS were supported by NIMH MH65413. GAF was supported by NIMH K23MH114023 and JUB was supported by NIMH K01MH083052. JAC was supported by NIMH 5T32MH112485. BF was supported by NIMH T32MH018921.

CMS was supported by NIMH K23MH109983 and R01MH122389. NJ was supported by R01MH117601. DSP was supported by ZIA-MH-002781. In addition, GAF received support from the One Mind – Basczucki Brain Research Fund. JAC was additionally supported by the Louis V. Gerstner III Research Scholar Award.

HO was supported by the American Foundation for Suicide Prevention (YIG-1-141-20). RS was supported by the McNair Foundation (MIND-MB), VHA (CX000994, CX001937). PMP was supported by the foundation for Research Support of the State of São Paulo (FAPESP 2014 / 50917-0), Brazil and the National Council for Scientific and Technological Development CNPq 465550/2014-2, Brazil. AT was supported by NARSAD/ Brain and Behavioral Research Foundation. KR was supported by the European Research Council (grant# ERC_CoG-2017_772337). QG was supported by the National Natural Science Foundation of China (Project Nos. 82120108014 and 81621003). SL acknowledges the support from Humboldt Foundation Friedrich Wilhelm Bessel Research Award. AH (Louvain) was supported by the F.R.S.-FNRS Belgian Science Foundation (Grant “1.C.059.18F”) and by the Belgian Fund for Scientific Research (F.R.S.-FNRS, Belgium) as Research Associate. AGGD was funded by the SA-MRC under the MRC Clinician Researcher Programme; the National Technologies in Medicine and the Biosciences Initiative (NTEMBI), managed by the South African Nuclear Energy Corporation (Necsa) and funded by the Department of Science and Innovation; and Harry Crossley Foundation. TF was supported by the Swedish Research Council, the Swedish Brain Foundation, and Riksbankens Jubileumsfond. KNTM was supported by the Swedish Research Council (2018-06729).

CONFLICT OF INTEREST

PMP received payment or honoraria for lectures and presentations in educational events for Sandoz, Daiichi Sankyo, Eurofarma, Abbot, Libbs, Instituto Israelita de Pesquisa e Ensino Albert Einstein, Instituto D’Or de Pesquisa e Ensino. HJG has received travel grants and speakers honoraria from Fresenius Medical Care, Neuraxpharm, Servier and Janssen Cilag as well as research funding from Fresenius Medical Care. PMT and NJ received a research grant from Biogen, Inc., unrelated to the topic of this manuscript. DJS received research grants and/or consultancy honoraria from Lundbeck and Sun.

REFERENCES

- (1). American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5[®]). American Psychiatric Pub; 2013.
- (2). Stein MB, Kean YM. Disability and quality of life in social phobia: epidemiologic findings. *Am J Psychiatry* 2000;157(10):1606–1613. [PubMed: 11007714]
- (3). Alden LE, Taylor CT. Interpersonal processes in social phobia. *Clin Psychol Rev* 2004;24(7):857–882. [PubMed: 15501559]
- (4). Fehm L, Pelissolo A, Furmark T, Wittchen H. Size and burden of social phobia in Europe. *European neuropsychopharmacology* 2005;15(4):453–462. [PubMed: 15921898]
- (5). Kessler RC, Petukhova M, Sampson NA, Zaslavsky AM, Wittchen H. Twelve-month and lifetime prevalence and lifetime morbid risk of anxiety and mood disorders in the United States. *International journal of methods in psychiatric research* 2012;21(3):169–184. [PubMed: 22865617]
- (6). Stein DJ, Lim CC, Roest AM, De Jonge P, Aguilar-Gaxiola S, Al-Hamzawi A, et al. The cross-national epidemiology of social anxiety disorder: Data from the World Mental Health Survey Initiative. *BMC medicine* 2017;15(1):143. [PubMed: 28756776]
- (7). Beesdo K, Knappe S, Pine DS. Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V. *Psychiatr Clin North Am* 2009 Sep;32(3):483–524. [PubMed: 19716988]
- (8). Lijster JM, Dierckx B, Utens EM, Verhulst FC, Zieldorff C, Dieleman GC, et al. The Age of Onset of Anxiety Disorders. *Can J Psychiatry* 2017 Apr;62(4):237–246. [PubMed: 27310233]
- (9). Beesdo K, Bittner A, Pine DS, Stein MB, Höfler M, Lieb R, et al. Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life. *Arch Gen Psychiatry* 2007 Aug; 64(8):903–912.
- (10). Bruehl AB, Delsignore A, Komossa K, Weidt S. Neuroimaging in social anxiety disorder—a meta-analytic review resulting in a new neurofunctional model. *Neuroscience & Biobehavioral Reviews* 2014 Nov;47:260–80. [PubMed: 25124509]
- (11). Caouette JD, Guyer AE. Gaining insight into adolescent vulnerability for social anxiety from developmental cognitive neuroscience. *Developmental cognitive neuroscience* 2014;8:65–76. [PubMed: 24239049]

- (12). Fox AS, Kalin NH. A translational neuroscience approach to understanding the development of social anxiety disorder and its pathophysiology. *Am J Psychiatry* 2014;171(11):1162–1173. [PubMed: 25157566]
- (13). LeDoux JE, Pine DS. Using neuroscience to help understand fear and anxiety: a two-system framework. *Am J Psychiatry* 2016.
- (14). Irle E, Ruhleder M, Lange C, Seidler-Brandler U, Salzer S, Dechent P, et al. Reduced amygdalar and hippocampal size in adults with generalized social phobia. *J Psychiatry Neurosci* 2010 Mar;35(2):126–131. [PubMed: 20184810]
- (15). Liao W, Xu Q, Mantini D, Ding J, Machado-de-Sousa JP, Hallak JE, et al. Altered gray matter morphometry and resting-state functional and structural connectivity in social anxiety disorder. *Brain Res* 2011;1388:167–177. [PubMed: 21402057]
- (16). Meng Y, Lui S, Qiu C, Qiu L, Lama S, Huang X, et al. Neuroanatomical deficits in drug-naive adult patients with generalized social anxiety disorder: a voxel-based morphometry study. *Psychiatry Research: Neuroimaging* 2013;214(1):9–15.
- (17). Mueller SC, Aouidad A, Gorodetsky E, Goldman D, Pine DS, Ernst M. Gray matter volume in adolescent anxiety: an impact of the brain-derived neurotrophic factor Val66Met polymorphism? *Journal of the American Academy of Child & Adolescent Psychiatry* 2013;52(2):184–195. [PubMed: 23357445]
- (18). Machado-de-Sousa JP, de Lima Osório F, Jackowski AP, Bressan RA, Chagas MH, Torro-Alves N, et al. Increased amygdalar and hippocampal volumes in young adults with social anxiety. *PLoS one* 2014;9(2):e88523. [PubMed: 24523911]
- (19). Suor JH, Jimmy J, Monk CS, Phan KL, Burkhouse KL. Parsing differences in amygdala volume among individuals with and without social and generalized anxiety disorders across the lifespan. *J Psychiatr Res* 2020;128:83–89. [PubMed: 32544774]
- (20). Syal S, Hattingh CJ, Fouché J, Spottiswoode B, Carey PD, Lochner C, et al. Grey matter abnormalities in social anxiety disorder: a pilot study. *Metab Brain Dis* 2012;27(3):299–309. [PubMed: 22527992]
- (21). Talati A, Pantazatos SP, Schneier FR, Weissman MM, Hirsch J. Gray matter abnormalities in social anxiety disorder: primary, replication, and specificity studies. *Biol Psychiatry* 2013;73(1):75–84. [PubMed: 22748614]
- (22). Jayakar R, Tone EB, Crosson B, Turner JA, Anderson PL, Phan KL, et al. Amygdala volume and social anxiety symptom severity: Does segmentation technique matter? *Psychiatry Research: Neuroimaging* 2020;295:111006. [PubMed: 31760338]
- (23). Bas-Hoogendam JM, van Steenberg H, Pannekoek JN, Fouché J, Lochner C, Hattingh CJ, et al. Voxel-based morphometry multi-center mega-analysis of brain structure in social anxiety disorder. *NeuroImage: Clinical* 2017;16:678–688.
- (24). Wang X, Cheng B, Luo Q, Qiu L, Wang S. Gray matter structural alterations in social anxiety disorder: a voxel-based meta-analysis. *Frontiers in psychiatry* 2018;9:449. [PubMed: 30298028]
- (25). Zhao Y, Chen L, Zhang W, Xiao Y, Shah C, Zhu H, et al. Gray matter abnormalities in non-comorbid medication-naive patients with major depressive disorder or social anxiety disorder. *EBioMedicine* 2017;21:228–235. [PubMed: 28633986]
- (26). Sindermann L, Redlich R, Opel N, Böhnlein J, Dannlowski U, Lehr EJ. Systematic transdiagnostic review of magnetic-resonance imaging results: depression, anxiety disorders and their co-occurrence. *J Psychiatr Res.* 2021;142:226–239. [PubMed: 34388482]
- (27). Strawn JR, Lu L, Peris TS, Levine A, Walkup JT. Research Review: Pediatric anxiety disorders—what have we learnt in the last 10 years? *Journal of Child Psychology and Psychiatry* 2021;62(2):114–139. [PubMed: 32500537]
- (28). Gold AL, Steuber ER, White LK, Pacheco J, Sachs JF, Pagliaccio D, et al. Cortical thickness and subcortical gray matter volume in pediatric anxiety disorders. *Neuropsychopharmacology* 2017;42(12):2423–2433. [PubMed: 28436445]
- (29). Liu Z, Hu Y, Zhang Y, Liu W, Zhang L, Wang Y, et al. Altered gray matter volume and structural co-variance in adolescents with social anxiety disorder: evidence for a delayed and unsynchronized development of the fronto-limbic system. *Psychol Med* 2020:1–10.

- (30). Bas-Hoogendam JM, Groenewold NA, Aghajani M, Freitag GF, Harrewijn A, Hilbert K, et al. ENIGMA-anxiety working group: Rationale for and organization of large-scale neuroimaging studies of anxiety disorders. *Hum Brain Mapp* 2022;43(1):83–112. [PubMed: 32618421]
- (31). Groenewold NA, Bas-Hoogendam JM, Aghajani M, Hilbert K, Zugman A, Fullana MA, et al. Brain characteristics associated with anxiety disorders: an update from the ENIGMA-Anxiety Working Group. *Journal of Neural Transmission* 2021;128(11):1807–1808.
- (32). Zugman A, Harrewijn A, Cardinale EM, Zwiebel H, Freitag GF, Werwath KE, et al. Mega-analysis methods in ENIGMA: The experience of the generalized anxiety disorder working group. *Hum Brain Mapp* 2022;43(1):255–277. [PubMed: 32596977]
- (33). Boedhoe PS, Heymans MW, Schmaal L, Abe Y, Alonso P, Ameis SH, et al. An empirical comparison of meta-and mega-analysis with data from the ENIGMA obsessive-compulsive disorder working group. *Frontiers in neuroinformatics* 2019;12:102. [PubMed: 30670959]
- (34). Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. *Neuron* 2002;33(3):341–355. [PubMed: 11832223]
- (35). Nakagawa S, Cuthill IC. Effect size, confidence interval and statistical significance: a practical guide for biologists. *Biological reviews* 2007;82(4):591–605. [PubMed: 17944619]
- (36). van Velzen LS, Kelly S, Isaev D, Aleman A, Aftanas LI, Bauer J, et al. White matter disturbances in major depressive disorder: a coordinated analysis across 20 international cohorts in the ENIGMA MDD working group. *Mol Psychiatry* 2020;25(7):1511–1525. [PubMed: 31471575]
- (37). Liebowitz M Liebowitz social anxiety scale. *Mod Probl Pharmacopsychiatry* 1987;22:141–173. [PubMed: 2885745]
- (38). Spielberger CD State-trait anxiety inventory for adults. 1983.
- (39). Beck AT, Steer RA, Brown G. Beck depression inventory–II. *Psychol Assess* 1996.
- (40). Harville DA Maximum likelihood approaches to variance component estimation and to related problems. *Journal of the American statistical association* 1977;72(358):320–338.
- (41). Bas-Hoogendam JM Commentary: Gray matter structural alterations in social anxiety disorder: A voxel-based meta-analysis. *Frontiers in psychiatry* 2019;10:1. [PubMed: 30723425]
- (42). Wang X, Cheng B, Wang S, Lu F, Luo Y, Long X, et al. Distinct grey matter volume alterations in adult patients with panic disorder and social anxiety disorder: A systematic review and voxel-based morphometry meta-analysis. *J Affect Disord* 2021;281:805–823. [PubMed: 33243552]
- (43). Bas-Hoogendam JM, van Steenbergen H, Tissier RL, Houwing-Duistermaat JJ, Westenberg PM, van der Wee, Nic JA. Subcortical brain volumes, cortical thickness and cortical surface area in families genetically enriched for social anxiety disorder–A multiplex multigenerational neuroimaging study. *EBioMedicine* 2018;36:410–428. [PubMed: 30266294]
- (44). Ho TC, Gutman B, Pozzi E, Grabe HJ, Hosten N, Wittfeld K, et al. Subcortical shape alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder Working Group. *Hum Brain Mapp* 2022;43(1):341–351. [PubMed: 32198905]
- (45). Harrewijn A, Cardinale EM, Groenewold NA, Bas-Hoogendam JM, Aghajani M, Hilbert K, et al. Cortical and subcortical brain structure in generalized anxiety disorder: findings from 28 research sites in the ENIGMA-Anxiety Working Group. *Translational psychiatry* 2021;11(1):1–15. [PubMed: 33414379]
- (46). Cremers HR, Veer IM, Spinhoven P, Rombouts SA, Roelofs K. Neural sensitivity to social reward and punishment anticipation in social anxiety disorder. *Frontiers in behavioral neuroscience* 2015;8:439. [PubMed: 25601830]
- (47). Crane NA, Chang F, Kinney KL, Klumpp H. Individual differences in striatal and amygdala response to emotional faces are related to symptom severity in social anxiety disorder. *Neuroimage: Clinical* 2021;30:102615. [PubMed: 33735785]
- (48). Thompson PM, Jahanshad N, Ching CR, Salminen LE, Thomopoulos SI, Bright J, et al. ENIGMA and global neuroscience: A decade of large-scale studies of the brain in health and disease across more than 40 countries. *Translational psychiatry* 2020;10(1):1–28. [PubMed: 32066695]

- (49). Boedhoe PS, Schmaal L, Abe Y, Ameis SH, Arnold PD, Batistuzzo MC, et al. Distinct subcortical volume alterations in pediatric and adult OCD: a worldwide meta-and mega-analysis. *Am J Psychiatry* 2017;174(1):60–69. [PubMed: 27609241]
- (50). Van Rooij D, Anagnostou E, Arango C, Auzias G, Behrmann M, Busatto GF, et al. Cortical and subcortical brain morphometry differences between patients with autism spectrum disorder and healthy individuals across the lifespan: results from the ENIGMA ASD Working Group. *Am J Psychiatry* 2018;175(4):359–369. [PubMed: 29145754]
- (51). Cohen J (1988). *Statistical power analysis for the behavioral sciences* (2nd ed.). Hillsdale, NJ: Erlbaum.
- (52). Logue MW, van Rooij SJ, Dennis EL, Davis SL, Hayes JP, Stevens JS, et al. Smaller hippocampal volume in posttraumatic stress disorder: a multisite ENIGMA-PGC study: subcortical volumetry results from posttraumatic stress disorder consortia. *Biol Psychiatry* 2018;83(3):244–253. [PubMed: 29217296]
- (53). Schmaal L, Veltman DJ, van Erp TG, Sämann P, Frodl T, Jahanshad N, et al. Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group. *Mol Psychiatry* 2016;21(6):806–812. [PubMed: 26122586]
- (54). Van Erp TG, Hibar DP, Rasmussen JM, Glahn DC, Pearlson GD, Andreassen OA, et al. Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. *Mol Psychiatry* 2016;21(4):547–553. [PubMed: 26033243]
- (55). Glascher J, Adolphs R. Processing of the arousal of subliminal and supraliminal emotional stimuli by the human amygdala. *J Neurosci* 2003 Nov 12;23(32):10274–10282. [PubMed: 14614086]
- (56). Baas D, Aleman A, Kahn RS. Lateralization of amygdala activation: a systematic review of functional neuroimaging studies. *Brain Res Rev* 2004;45(2):96–103. [PubMed: 15145620]
- (57). Cooney RE, Atlas LY, Joormann J, Eugène F, Gotlib IH. Amygdala activation in the processing of neutral faces in social anxiety disorder: is neutral really neutral? *Psychiatry Research: Neuroimaging* 2006;148(1):55–59.
- (58). Van der Merwe C, Jahanshad N, Cheung JW, Mufford M, Groenewold NA, Koen N, et al. Concordance of genetic variation that increases risk for anxiety disorders and posttraumatic stress disorders and that influences their underlying neurocircuitry. *J Affect Disord* 2019;245:885–896. [PubMed: 30699873]
- (59). Haller SP, Mills KL, Hartwright CE, David AS, Kadosh KC. When change is the only constant: The promise of longitudinal neuroimaging in understanding social anxiety disorder. *Developmental cognitive neuroscience* 2018;33:73–82. [PubMed: 29960860]




Figure 1:
Schematic overview of the seven subcortical brain regions segmented for each hemisphere.
Abbreviations: THA=thalamus; HIP=hippocampus; AMY=amygdala; CAU=caudate;
PU=putamen; PA=pallidum; NACC=(nucleus) accumbens.




Figure 2: Mixed-effects d effect size and Standard Error (SE) for differences in subcortical brain volume between social anxiety disorder (SAD) and healthy control (HC) participants, obtained in mega-analyses that were adjusted for sex, age, age², sex-by-age, sex-by-age² and total ICV.
Top panel: Full age range. **Bottom panel:** Stratified according to adult and adolescent age group.

* $p < 0.05$ after family-wise error correction for multiple comparisons.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1:

Demographic information for samples included in the mega-analysis of subcortical volumes in social anxiety disorder patients versus healthy controls.

Sample	Country	Diagnostic Interview	Social Anxiety Disorder (SAD)				Healthy Controls (HC)			
			N	Sex % Female	Age mean ± sd	Adults % >21 yrs	N	Sex % Female	Age mean ± sd	Adults % >21 yrs
1	US	SCID	59	33.9	30.1 ± 11.7	78.0	48.0	28.8 ± 9.7	81.3	
2	BR	DAWBA	15	46.7	13.5 ± 1.9	0.0	54.5	13.2 ± 2.1	0.0	
3	BR	DAWBA	12	41.7	12.8 ± 1.7	0.0	37.5	12.6 ± 1.6	0.0	
4	US	Other	50	74.0	15.4 ± 1.7	0.0	59.1	14.8 ± 1.8	0.0	
5	US	Other	17	64.7	29.1 ± 8.9	88.2	58.8	31.4 ± 10.8	88.2	
6	US	SCID	16	81.3	34.6 ± 8.3	100.0	44.4	31.6 ± 8.2	100.0	
7	NL	MINI	23	56.5	33.2 ± 11.7	82.6	66.7	32.1 ± 10.8	83.3	
8	ES	Other	63	66.7	24.0 ± 6.1	55.6	56.6	28.3 ± 9.6	73.7	
9	DE	CIDI	20	60.0	24.6 ± 5.7	60.0	61.9	25.8 ± 5.7	90.5	
10	DE	SCID	29	69.0	30.4 ± 9.2	82.8	62.5	34.8 ± 12.8	92.5	
11	DE	SCID	27	63.0	38.8 ± 13.3	85.2	64.7	28.1 ± 10.1	82.8	
12	DE	SCID	12	50.0	23.3 ± 3.4	66.7	50.0	25.3 ± 2.1	92.9	
13	CN	SCID	19	31.6	21.6 ± 3.8	36.8	30.0	21.5 ± 3.8	35.0	
14	US	SCID	34	44.1	29.2 ± 15.2	58.8	44.1	29.1 ± 15.2	58.8	
15	TR	SCID	30	26.7	32.6 ± 6.5	100.0	38.1	30.9 ± 6.0	100.0	
16	NL	MINI	10	70.0	45.6 ± 4.5	100.0	36.4	47.1 ± 12.3	90.9	
17	BE	MINI	23	100.0	22.7 ± 3.1	73.9	100.0	22.7 ± 3.9	65.2	
18	NL	MINI	20	45.0	28.9 ± 7.9	80.0	42.1	27.7 ± 8.0	89.5	
19	DE	SCID	45	62.2	27.5 ± 7.0	91.1	63.0	26.7 ± 4.8	97.8	
20	ZA	SCID	11	72.7	32.1 ± 8.3	81.8	11	63.6	32.2 ± 8.9	90.9
21	ZA	SCID	11	54.5	28.5 ± 7.8	81.8	11	36.4	28.9 ± 7.3	72.7
22	DE	SCID	19	42.1	36.1 ± 14.6	89.5	22	27.3	31.8 ± 9.0	86.4
23	NL	CIDI	35	54.3	37.9 ± 9.9	97.1	21	61.9	39.8 ± 9.2	100.0
24	NL	CIDI	33	69.7	37.8 ± 10.1	93.9	27	74.1	40.3 ± 9.6	96.3
25	NL	CIDI	34	73.5	37.7 ± 9.6	97.1	11	54.5	44.6 ± 9.7	100.0
26	US	Other	155	61.3	14.7 ± 3.4	0.0	398	48.0	14.1 ± 4.0	1.0
27	US	SCID&KSADS	30	73.3	12.5 ± 3.3	0.0	22	50.0	12.1 ± 2.3	0.0

Sample	Country	Diagnostic Interview	Social Anxiety Disorder (SAD)				Healthy Controls (HC)			
			N	Sex % Female	Age mean ± sd	Adults % >21 yrs	N	Sex % Female	Age mean ± sd	Adults % >21 yrs
28	DE	CIDI	29	62.1	52.3 ± 10.8	100.0	397	46.6	53.6 ± 10.9	100.0
29	DE	SP_Munster	67	79.1	32.9 ± 11.0	91.0	490	55.7	37.3 ± 11.9	92.2
30	DE	TIP	14	64.3	23.9 ± 4.2	64.3	23	91.3	23.7 ± 8.1	47.8
31	US	UCSD_Ball	15	66.7	21.2 ± 2.2	46.7	18	66.7	18.6 ± 0.8	0.0
32	US	UCSD_Sapient	25	60.0	26.1 ± 8.7	64.0	25	64.0	28.0 ± 8.2	80.0
33	US	UJC	12	75.0	27.9 ± 7.2	91.7	11	63.6	32.7 ± 11.2	90.9
34	SE	UME_I	26	84.6	32.3 ± 9.6	88.5	23	69.6	32.3 ± 10.7	87.0
35	SE	UME_II	46	63.0	30.7 ± 8.3	89.1	42	57.1	31.9 ± 9.5	90.5
36	US	Vanderbilt	10	60.0	22.1 ± 2.0	60.0	14	64.3	23.0 ± 1.7	71.4
37	US	Washington	19	52.6	10.2 ± 1.5	0.0	28	50.0	9.9 ± 1.2	0.0
Total across all samples			1115	61.5	26.9 ± 12.3	60.5	2775	55.2	31.9 ± 15.6	71.6

Abbreviations: SCID=Structured Clinical Interview for DSM-IV disorders; DAWBA=Development and Well-Being Behavior Assessment; MINI=Mini-International Neuropsychiatric Interview; CIDI=Composite Interview Diagnostic Instrument; KSADS= Kiddie Schedule for Affective Disorders and Schizophrenia for school-age children.

Notes:

¹The Philadelphia Neuroimaging Cohort (PNC) and Study of Health in Pomerania (SHIP) assessed lifetime but not current SAD diagnosis.

Table 2: Clinical characteristics for samples included in the meta-analysis and mega-analysis (selectively reported for social anxiety disorder patients)

Sample	Lifetime comorbidity			Psychotropic medication ¹			Age of onset		LSAS	STAT	BDI-II
	% ANX	% MDD	% Any use	% SSRI/SNRI	mean ± sd	% Early onset ²	mean ± sd	mean ± sd	mean ± sd	mean ± sd	
1 BCM	37.3	62.7	69.5	45.8	3	-	-	-	-	-	
2 BHRC_RS	40.0	46.7	13.3	6.7	-	26.7	-	-	-	-	
3 BHRC_SP	41.7	25.0	0.0 ⁴	0.0	-	33.3	-	-	-	-	
4 Boystown	58.0	38.0	52.0	28.0	-	6.0	67.6 ± 22.7	-	-	-	
5 Columbia_SAD	17.6	35.3	0.0	0.0	-	-	81.4 ± 15.6	-	-	-	
6 Columbia_SPP	31.3	31.3	18.8	12.5	10.6 ± 6.0	68.8	-	39.1 ± 9.1	-	-	
7 DCCN	21.7	17.4	0.0	0.0	-	-	66.9 ± 20.3	-	-	13.0 ± 7.6	
8 DelMar	0.0	0.0	0.0	0.0	-	-	83.4 ± 17.2	40.4 ± 5.6	-	-	
9 Dresden	25.0	35.0	0.0	0.0	11.8 ± 6.1	25.0	58.1 ± 30.2	49.0 ± 11.2	12.4 ± 7.5	-	
10 FOR2107_MIR	48.3	100.0	82.8	69.0	-	-	-	62.0 ± 7.4	22.8 ± 9.4	-	
11 FOR2107_MS	37.0	100.0	66.7	66.7	-	-	-	57.7 ± 9.7	21.9 ± 11.0	-	
12 Fortuene	8.3	25.0	0.0	0.0	-	-	62.9 ± 17.7	48.2 ± 7.9	10.4 ± 5.7	-	
13 HMRRC	0.0	0.0	0.0	0.0	17.2 ± 5.9	21.1	52.0 ± 14.0	-	-	-	
14 Houston	41.2	100.0	11.8	-	10.1 ± 5.2	26.5	-	-	26.1 ± 15.2	-	
15 Istanbul	6.7	0.0	0.0	0.0	-	-	73.1 ± 17.8	-	-	-	
16 LFLSAD	40.0	50.0	10.0	10.0	6.0 ± 2.7	100.0	65.9 ± 23.0	43.8 ± 9.1	13.6 ± 10.5	-	
17 Louvain	0.0	0.0	0.0	0.0	-	-	74.2 ± 11.1	51.0 ± 9.3	15.7 ± 8.4	-	
18 LUMC	0.0	25.0	10.0	10.0	-	-	85.7 ± 13.5	-	19.1 ± 9.1	-	
19 MPack	17.8	15.6	15.6	11.1	-	-	66.6 ± 17.7	52.5 ± 9.5	14.4 ± 11.4	-	
20 MRC_SU	0.0	0.0	0.0	0.0	16.4 ± 9.0	27.3	85.3 ± 24.2	53.3 ± 10.7	15.5 ± 11.6	-	
21 MRC_UCT	9.1	0.0	9.1	-	14.6 ± 5.7	27.3	78.8 ± 30.8	-	-	-	
22 MSAD	26.3	31.6	0.0	0.0	-	-	66.8 ± 15.0	-	13.6 ± 9.6	-	
23 NESDA_Ams	74.3	80.0	45.7	34.3	12.9 ± 6.3	54.3	3	-	-	-	
24 NESDA_Lei	84.8	81.8	48.5	33.3	13.6 ± 8.9	57.6	-	-	-	-	
25 NESDA_Gro	85.3	82.4	55.9	38.2	20.2 ± 12.6	32.4	-	-	-	-	
26 PNC	53.5	15.5	12.3	3.2	-	25.2	-	34.4 ± 9.2	-	-	

Sample	Lifetime comorbidity		Psychotropic medication ¹		Age of onset		LSAS	STAI-T	BDI-II	
	% ANX	% MDD	% Any use	% SSRI/SNRI	mean ± sd	% Early onset ²				mean ± sd
27	SDAN	80.0	3.3	0.0 ⁴	0.0	-	50.0	-	35.8 ± 10.2	-
28	SHIP	65.5	62.1	41.4	13.8	21.6 ± 17.1	51.7	-	-	15.8 ± 11.5
29	SP_Munster	16.4	52.2	25.4	25.4	17.6 ± 12.3	28.4	60.5 ± 19.5	55.7 ± 11.2	17.2 ± 10.9
30	TIP	0.0	78.6	35.7	35.7	14.0 ± 6.9	28.6	66.0 ± 22.9	52.8 ± 12.7	10.1 ± 8.7
31	UCSD_Ball	6.7	40.0	0.0	0.0	-	-	57.9 ± 19.4	57.5 ± 13.6	20.1 ± 12.4
32	UCSD_Sapient	0.0	0.0	0.0	0.0	-	-	-	54.7 ± 8.4	14.6 ± 10.1
33	UIC	50.0	8.3	0.0	0.0	13.9 ± 6.4	41.7	82.7 ± 18.6	55.2 ± 11.0	16.8 ± 10.7
34	UME_I	-	0.0	34.6	30.8	15.9 ± 6.0	19.2	76.3 ± 18.7	-	-
35	UME_II	26.1	65.2	8.7	8.7	13.8 ± 4.7	28.3	78.0 ± 19.0	43.4 ± 9.1	-
36	Vanderbilt	80.0	20.0	0.0	0.0	14.0 ± 4.2	10.0	-	47.7 ± 10.6	12.6 ± 11.1
37	Washington	73.7	15.8	5.3	0.0	5.4 ± 2.3	100.0	-	-	-
Total across all samples		35.9	37.5	22.2	15.2	14.9 ± 9.8	21.5	71.2 ± 21.1	46.4 ± 13.3	16.5 ± 10.9

Abbreviations: LSAS=Liebowitz Social Anxiety Scale; STAI-T=State-Trait Anxiety Inventory-Trait; BDI-II=Beck Depression Inventory 2nd Edition; ANX=Any comorbid anxiety disorder; MDD=Major Depressive Disorder, SSRI=Selective Serotonin Reuptake Inhibitor; SNRI=Serotonin-Norepinephrine Reuptake Inhibitor; sd=standard deviation.

Notes:

¹ Medication use at time of scan (% in full sample);

² Defined as social anxiety disorder onset prior to 13 years of age;

³ Information not recorded in this sample (-);

⁴ Not included in this sample (n=0).

Table 3:

Overview of mega-analytic results for main diagnostic group comparisons and clinical subgroup comparisons: sample sizes, effect sizes and p-values.

Group Comparison	Sens. Samples		SAD		HC		L-Putamen/		R-Putamen		L-Pallidum		R-Pallidum		L-Accumbens		L-Amygdala ¹		R-Hippocampus			
	Age	N	N	N	N	N	Mixeff.d	P _{FWE} ^{2,3}	Mixeff.d	P _{FWE}	Mixeff.d	P _{FWE}	Mixeff.d	P _{FWE}	Mixeff.d	P _{FWE}	Mixeff.d	P _{FWE} ^{2,3}	Mixeff.d	P _{FWE}		
SAD vs HC	-	37	1120	2781	-0.077	0.037	-0.104	0.001	0.058	0.572	0.065	0.186	ns	ns	-0.068	0.308	-0.066	0.359	ns	ns		
SAD vs HC	Adu	30	668	1984	-0.141	< 0.001	-0.158	< 0.001	0.129	0.006	0.099	0.046	ns	ns	-0.076	0.674	ns	ns	ns	ns		
SAD vs HC	Ado	29	437	788	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns		
SAD ANX vs HC	-	29	404	2538	ns	ns	-0.105	0.185	ns	ns	ns	ns	ns	ns	-0.145	0.017	-0.120	0.137	ns	ns		
SAD ANX vs HC	Adu	22	208	1811	ns	ns	-0.198	0.010	ns	ns	ns	ns	ns	ns	-0.174	0.077	-0.155	0.164	ns	ns		
SAD ANX vs HC	Ado	15	191	661	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns		
SAD wo ANX vs HC	-	31	615	2613	-0.091	0.046	-0.097	0.029	0.105	0.051	0.081	0.184	ns	ns	ns	ns	ns	ns	ns	ns		
SAD wo ANX vs HC	Adu	25	388	1868	-0.146	0.003	-0.138	0.007	0.214	< 0.001	0.141	0.006	ns	ns	ns	ns	ns	ns	ns	ns		
SAD wo ANX vs HC	Ado	25	216	736	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns		
SAD MED vs HC	-	20	246	2384	ns	ns	-0.141	0.216	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	-0.143	0.282		
SAD MED vs HC	Adu	15	170	1704	-0.158	0.441	-0.198	0.096	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns		
SAD MED vs HC	Ado ⁴	11	75	645	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-		
SAD wo MED vs HC	-	37	850	2781	-0.081	0.058	-0.100	0.007	0.083	0.103	0.084	0.054	ns	ns	-0.068	0.523	ns	ns	ns	ns		
SAD wo MED vs HC	Adu	30	479	1984	-0.154	< 0.001	-0.157	< 0.001	0.170	0.001	0.132	0.008	ns	ns	ns	ns	ns	ns	ns	ns		
SAD wo MED vs HC	Ado	27	356	771	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns		
SAD E-ONS vs HC	-	23	240	1729	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	-0.194	0.009	
SAD E-ONS vs HC	Adu	15	136	1071	-0.229	0.040	-0.269	0.006	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	ns	-0.326	0.001
SAD E-ONS vs HC	Ado ⁴	12	98	621	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Group Comparison	Sens. Samples		HC	L-Putamen ¹		R-Putamen		L-Pallidum		R-Pallidum		L-Amygdala ¹		R-Hippocampus	
	N	N		N	Mixeff.d	P _{FWE}	Mixeff.d	P _{FWE}	Mixeff.d						
SAD L-ONS vs HC	16	200	1174	-0.336	<0.001	-0.309	<0.001	0.240	0.002	0.195	0.006	-0.171	0.024	ns	ns
SAD L-ONS vs HC	16	174	1078	-0.362	<0.001	-0.322	<0.001	0.260	0.001	0.199	0.006	-0.157	0.083	ns	ns
SAD L-ONS vs HC	7	22	38	-	-	-	-	-	-	-	-	-	-	-	-

Abbreviations: Sens. =sensitivity analysis by age group; SAD=social anxiety disorder; HC=healthy control; L=left; R=right; N=number of participants; Mixeff.d=mixed-effects d; FWE=family-wise error correction (Bonferroni); ns=non-significant (uncorrected p<0.05); Adu=adults; Ado=adolescents; ANX=any comorbid anxiety disorder; wo=without; MED=psychotropic medication use at time of scan; E-ONS=early onset; L-ONS=later onset.

Notes:

¹ Results presented for all regions with an FWE significant finding in one of the full age range mega-analyses;

² Bold text highlights significant result after FWE multiple comparison correction;

³ Plain text indicates uncorrected significant result;

⁴ Sensitivity analyses not performed – insufficient data available.